GROWTH HORMONE / PEPTIDE CARD

CJC-1295

A long-acting growth hormone-releasing hormone analog studied in early human pharmacology research.

PEPTIDE CARDCJC-1295

Reviewed
August 7, 2026

Human evidence

2/5 · Early human pharmacology

U.S. FDANot FDA approved

2026 WADAProhibited

Inspect 2 sources

On this page

WHAT THE EVIDENCE SAYS

CJC-1295 evidence summary.

CJC-1295 can produce measurable endocrine effects, but biomarker changes should not be confused with proven improvement in health outcomes.

Entity type
Peptide analogSource snapshot
August 7, 2026Record status
Sources attached

Do not overread this record

Marketed CJC-1295 products may differ in structure, including whether a drug-affinity complex is present.

01 / CLASSIFICATION

What is CJC-1295?

Entity typePeptide analog

Research categoryGrowth Hormone

Known namesCJC-1295

Editorial unitOne molecule or defined product record

Names, fragments, salts, formulations, routes, and branded products are kept distinct whenever transferring evidence would change the conclusion.

Class: Growth-hormone-axis peptides Goal: Growth Hormone Axis

02 / EVIDENCE

CJC-1295 human and preclinical evidence.

HUMAN

2/5 · Early human pharmacology

Small studies measured hormone responses; they do not establish long-term therapeutic outcomes.

PRECLINICAL

3/5 · Mechanism established

Long-acting GHRH analog activity is established, while clinical benefit remains uncertain.

The five-point bars describe the maturity and depth of the evidence base. They do not score effectiveness, safety, or personal suitability.

03 / STATUS

CJC-1295 FDA and sport status.

U.S. FDANo FDA-approved drug product.

2026 WADAProhibited at all times under the 2026 WADA List (S2).

Commercial accessPeptideAgent does not route unapproved research substances to sellers.

Status summaries are educational and time-sensitive. Consult current official labeling and anti-doping resources for a decision.

04 / RESEARCH AREAS

What is CJC-1295 being studied for?

01Growth hormone secretion

02IGF-1

03GHRH pharmacology

04Long-acting analogs

05 / COMPARISONS

Compare CJC-1295.

CJC-1295 vs IpamorelinEarly endocrine research compared without treating biomarker changes as outcomes.CJC-1295 vs SermorelinA long-acting GHRH analog compared with a shorter historical GHRH fragment.CJC-1295 vs TesamorelinAn unapproved endocrine research peptide compared with an indication-specific approved medicine.

06 / LATEST & DEFINING SOURCES

CJC-1295 primary and official sources.

Human trial / 2006Prolonged stimulation of growth hormone and IGF-1 by CJC-1295

PubMed

WADA / 20262026 Prohibited List

World Anti-Doping Agency

07 / QUESTIONS

Questions about CJC-1295.

Start with identity, research, human evidence, approval, sport status, and the limits of the current record.

EvidenceWhat is the evidence for CJC-1295?

CJC-1295 can produce measurable endocrine effects, but biomarker changes should not be confused with proven improvement in health outcomes.

ResearchWhat is CJC-1295 being studied for?

Current source-backed research areas include Growth hormone secretion, IGF-1, GHRH pharmacology, Long-acting analogs. These areas describe investigation, not established personal benefit.

FDA statusIs CJC-1295 FDA approved?

Current U.S. status for CJC-1295: No FDA-approved drug product.

Sport statusIs CJC-1295 prohibited in sport?

Current sport-status snapshot for CJC-1295: Prohibited at all times under the 2026 WADA List (S2).

Evidence limitsWhat are the main evidence limits for CJC-1295?

Marketed CJC-1295 products may differ in structure, including whether a drug-affinity complex is present.